Breast Biopsy Market by Product (Assay Kits, Biopsy Needles, Biopsy Tables), Type (Liquid Breast Biopsy, Needle Breast Biopsy, Open Surgical Breast Biopsy), Guidance, Application - Global Forecast 2024-2030

[192 Pages Report] The Breast Biopsy Market size was estimated at USD 1.00 billion in 2023 and expected to reach USD 1.09 billion in 2024, at a CAGR 9.26% to reach USD 1.87 billion by 2030.

A breast biopsy is a medical procedure for removing a sample of breast tissue for testing. The pathologists analyze the tissue sample in the medical labs to provide an appropriate medical diagnosis. The prevalence of breast cancer among women worldwide and the inclination of patients toward early diagnosis and treatment of diseases raise the need for diagnostic solutions such as breast biopsy procedures. Governments across countries are implementing breast cancer awareness programs encouraging individuals to undergo screening tests and necessitating advanced breast biopsy procedures. However, the high cost of breast biopsy procedures and the possibility of infections associated with the biopsy needles may prevent patients from undergoing the breast biopsy procedure. In addition, the ongoing clinical trials and the advent of liquid biopsy are expected to improve the diagnosis and patient outcome for breast cancer treatment.

The surge in the incidence of breast cancer cases among women and the increase in the availability of advanced diagnostic treatment, coupled with the ongoing research on breast biopsy procedures, have increased the adoption of breast biopsy procedures among breast cancer patients in the Americas. The growing need for appropriate diagnosis and treatment for breast cancer to reduce breast cancer-related casualties and mitigate breast cancer risk factors are the factors that necessitate patients to avail of breast biopsy diagnostic procedures in the APAC region. The EMEA region has a significant need for breast biopsy diagnostic procedures owing to the increasing breast cancer awareness in older women and the rising need for improved diagnostic solutions for breast cancer. Additionally, significant investments by public and private organizations to expand the research on breast cancer are expected to improve and advance breast biopsy procedures.

The market dynamics represent an ever-changing landscape of the Breast Biopsy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Breast Biopsy Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Breast Biopsy Market.

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Breast Biopsy Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

The value chain of the Breast Biopsy Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

The pricing analysis comprehensively evaluates how a product or service is priced within the Breast Biopsy Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Breast Biopsy Market.

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Breast Biopsy Market.

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Breast Biopsy Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

The trade analysis of the Breast Biopsy Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

The regulatory framework analysis for the Breast Biopsy Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Breast Biopsy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Breast Biopsy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

• Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio

  Quest Diagnostics and Haystack Oncology reached a definitive agreement for Quest to acquire Haystack through an all-cash equity transaction. This strategic acquisition will allow Quest to capitalize on its expertise and scale in oncology, genomics, and pathology. The initial focus of the development efforts will be on MRD tests for colorectal, breast, and lung cancers. Following the completion of the acquisition, Quest plans to incorporate the MRD test developed by Haystack starting in 2024. [Published On: 2023-04-17]

• Guardant Health Receives FDA Approval for Guardant360 CDx as Companion Diagnostic for Menarini Group’s ORSERDU for the Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

  Guardant Health, Inc. obtained FDA approval for their liquid biopsy test, Guardant360 CDx, as a companion diagnostic to detect ESR1 mutations in advanced or metastatic breast cancer patients who may benefit from treatment with ORSERDU. Menarini Group takes pride in introducing the first treatment targeting ESR1 mutations found in up to 40% of ER+/HER2- advanced breast cancers. [Published On: 2023-01-30]

• TransMed7, LLC Announces First Clinical Use of SpeedBird Breast Biopsy Devices for Commercial Launch

  TransMed7 LLC announced the successful clinical implementation of the Sparrow device, a member of their SpeedBird family of vacuum-assisted Single Insertion/Multiple Collection (SIMC) Breast Biopsy devices. TransMed7 has designed and developed the SpeedBird and Concorde platforms to address and overcome issues associated with outdated biopsy devices that have been used for decades. [Published On: 2022-08-10]

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Breast Biopsy Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

The report delves into recent significant developments in the Breast Biopsy Market, highlighting leading vendors and their innovative profiles. These include Argon Medical, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc, Biocept, Inc., Cook Group Incorporated, CooperSurgical, Inc., F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc., FUJIFILM Corporation, GE HealthCare, Guardant Health, Halma plc, Hologic, Inc., Illumina, Inc., INRAD, Inc., Iskus Health Ltd., Johnson & Johnson Services, Inc., Leica Biosystems Nussloch GmbH, Medtronic PLC, Merit Medical Systems, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific Inc., TransMed7, LLC, and Trivitron Healthcare.

This research report categorizes the Breast Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Assay Kits
  • Biopsy Needles
  • Biopsy Tables
  • Guidance Systems
  • Liquid Biopsy Instruments
  • Localization Wires
• Type
  • Liquid Breast Biopsy
    • Circulating Tumor Cells
    • Circulating Tumor DNA
  • Needle Breast Biopsy
    • Core Needle Biopsy
    • Fine Needle Aspiration Biopsy
    • Vacuum-Assisted Biopsy
  • Open Surgical Breast Biopsy
    • Excisional
    • Incisional
• Guidance
  • Image-Guided Biopsy
    • Mammography-Guided Stereotactic Biopsy
    • MRI Guided Biopsy
    • Ultrasound-Guided Biopsy
  • Liquid Biopsy
    • Microarray-Based Biopsy
    • NGS-Based Biopsy
    • PCR-Based Biopsy
• Application
  • Early Cancer Screening
  • Recurrence Monitoring
  • Therapy Selection
  • Treatment Monitoring

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

1. What is the current market size and projected growth?
2. Which products, segments, applications, and regions offer promising investment opportunities?
3. What are the prevailing technology trends and regulatory frameworks?
4. What is the market share and positioning of the leading vendors?
5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?